We are live on ! Find out more
AIM

AIM ImmunoTech
AIM

9 hedge funds and large institutions have $307K invested in AIM ImmunoTech in 2019 Q4 according to their latest regulatory filings, with 2 funds opening new positions, 1 increasing their positions, 2 reducing their positions, and 4 closing their positions.

New
Increased
Maintained
Reduced
Closed

18% less funds holding

Funds holding: 11 → 9 (-2)

50% less first-time investments, than exits

New positions opened: 2 | Existing positions closed: 4

50% less repeat investments, than reductions

Existing positions increased: 1 | Existing positions reduced: 2

68% less capital invested

Capital invested by funds: $970K → $307K (-$663K)

Holders
9
Holders Change
-2
Holders Change %
-18.18%
% of All Funds
0.18%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
2
Increased
1
Reduced
2
Closed
4
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

Rank Fund Capital Flow
1
SM
Sabby Management
Florida
+$173K
2
Renaissance Technologies
Renaissance Technologies
New York
+$8.68K
3
Deutsche Bank
Deutsche Bank
Germany
+$2.21K

Top Sellers

Rank Fund Capital Flow
1
AFM
Anson Funds Management
Texas
-$393K
2
Hudson Bay Capital Management
Hudson Bay Capital Management
Connecticut
-$301K
3
Morgan Stanley
Morgan Stanley
New York
-$72.2K
4
ARTA
A.R.T. Advisors
New York
-$9K
5
Bank of America
Bank of America
North Carolina
-$3.51K

AIM Hedge Fund Activity: Q4 2019 in Review

9 of the 5,092 institutional investors tracked by Wall St. Rank reported a position in AIM ImmunoTech (AIM) for Q4 2019, worth a combined $307K — down 68% from $970K a quarter earlier.

Sellers outnumbered buyers: 4 funds closed out of AIM and 2 opened new positions — a net loss of 2 holders — while 2 trimmed existing stakes and 1 added.

The largest buyer was Sabby Management, adding an estimated $173K. The largest seller was Anson Funds Management, exiting entirely with an estimated $393K sold.

  • 9 institutional investors held AIM ImmunoTech (AIM) as of Q4 2019, down from 11 in Q3 2019.
  • Funds reported $307K of AIM ImmunoTech stock for Q4 2019, down 68% quarter-over-quarter.
  • 2 funds opened new AIM ImmunoTech positions in Q4 2019 and 4 closed out, a net change of -2 holders.
  • The largest AIM ImmunoTech buyer in Q4 2019 was Sabby Management, an estimated $173K added.
  • The largest AIM ImmunoTech seller in Q4 2019 was Anson Funds Management, an estimated $393K sold.

Based on aggregated 13F filings for Q4 2019.